Executive Summary Antibody–drug conjugates (ADCs) have rapidly evolved from an innovative therapeutic modality into one of the most strategically important areas in the biotech industry. In recent years, the ADC market has undergone significant changes: A surge in licensing deals and M&A activity Increasing investment from large pharmaceutical companies in ADC pipelines Growing focus among biotech startups on ADC platform technologies These trends indicate that: The ADC mark